However, given differences in drug accessibility with our publicly funded healthcare model, there is a need to understand the real-world outcomes of patients with MM refractory to anti-CD38 mAbs, particularly those with triple class refractory (TCR) disease, outside of the United States. This evidence concerns the gene CD38 and Miyoshi myopathy.